Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period. METHODS: In this double-blind, placebo-controlled trial, 3889 patients (mean age, 73 years) were randomly assigned to receive a single 15-minute infusion of zoledronic acid (5 mg) and 3876 were assigned to receive placebo at baseline, at 12 months, and at 24 months; the patients were followed until 36 months. Primary end points were new vertebral fracture (in patients not taking concomitant osteoporosis medications) and hip fracture (in all patients). Secondary end points included bone mineral density, bone turnover markers, and safety outcomes. RESULTS: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo (3.3% in the zoledronic-acid group vs. 10.9% in the placebo group; relative risk, 0.30; 95% confidence interval [CI], 0.24 to 0.38) and reduced the risk of hip fracture by 41% (1.4% in the zoledronic-acid group vs. 2.5% in the placebo group; hazard ratio, 0.59; 95% CI, 0.42 to 0.83). Nonvertebral fractures, clinical fractures, and clinical vertebral fractures were reduced by 25%, 33%, and 77%, respectively (P<0.001 for all comparisons). Zoledronic acid was also associated with a significant improvement in bone mineral density and bone metabolism markers. Adverse events, including change in renal function, were similar in the two study groups. However, serious atrial fibrillation occurred more frequently in the zoledronic acid group (in 50 vs. 20 patients, P<0.001). CONCLUSIONS: A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“There is abundant evidence that the elevated risk of fracture in patients with osteoporosis by BMD is reduced with pharmacotherapy [52, 57, 59–70].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
In the citing paper
“Zoledronic acid reduces the incidence of vertebral fractures by 70 % (with significant reduction at 1 year), hip fractures by 41 %, and nonvertebral fractures by 25 % over 3 years in patients with osteoporosis defined by prevalent vertebral fractures and osteoporosis by BMD of the hip [66].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [66]
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationVertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277
Self-citationOsteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationSystematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Woo, S.-B., Hellstein, J. W., & Kalmar, J. R. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00009 · Cited by 1,252
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Self-citation
Cited by
Items 301–400 of 1,004
Osteoporosis Disease Management: What Every Orthopaedic Surgeon Should Know
Dell, R. M., Greene, D. F., Anderson, D., & Williams, K. (2009) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.i.00521 · Cited by 103
Ominsky, M. S., Stouch, B., Schroeder, J., Pyrah, I. T. G., Stolina, M., Smith, S. Y., & Kostenuik, P. J. (2011) · Bone · doi:10.1016/j.bone.2011.04.001 · Cited by 101
“Placebo-controlled clinical trials of antiresorptive agents in postmenopausal women with osteoporosis (PMO) demonstrate that the reduction of bone remodeling for up to 5 years can reduce fracture risk [1–5].”
BackgroundPopp, A. W., Guler, S. A., Lamy, O., Senn, C., Buffat, H., Perrelet, R., Hans, D. B., & Lippuner, K. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1775 · Cited by 105
“Full details on the HORIZON trial design and results have been published.((24))”
BackgroundMethodResultInfluentialCummings, S. R., Lui, L., Eastell, R., & Allen, I. E. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2779 · Cited by 107
Self-citationVasikaran, S. D. (2008) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360801949442 · Cited by 97
Bawa, H. S., Weick, J. W., & Dirschl, D. R. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.n.01275 · Cited by 104
Delmas, P. D., McClung, M. R., Zanchetta, J., Racewicz, A. J., Roux, C., Benhamou, C.-L., Man, Z., Eusebio, R. A., Beary, J. F., Burgio, D. E., et al. (2007) · Bone · doi:10.1016/j.bone.2007.09.001 · Cited by 100
“The incidence declined with subsequent infusions [16].”
Self-citationAtrial fibrillation and bisphosphonate therapy
Pazianas, M., Compston, J. E., & Huang, C. L.-H. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091201 · Cited by 100
Hopkins, R. B., Goeree, R. A., Pullenayegum, E., Adachi, J. D., Παπαϊωάννου, Α., Xie, F., & Thabane, L. (2011) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-12-209 · Cited by 104
“For the 9 drugs, 6 studies were for alendronate [26-31], 1 study for denosumab [32], 8 studies for etidronate [33-40], 4 studies for ibandronate [41-44], 1 study for raloxifene [45], 6 studies for risedronate [46-51], 2 studies for strontium [52,53], 1 for teriparatide [54], and 1 for zoledronic Acid [55].”
BackgroundHuang, J. S., Meixner, L., Fernández, S. L., & McCutchan, J. A. (2008) · AIDS · doi:10.1097/qad.0b013e32831c8adc · Cited by 100
“improvements in bone density and reduction in fracture risk [15,16].”
BackgroundResultZoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis
Dhillon, S. (2016) · Drugs · doi:10.1007/s40265-016-0662-4 · Cited by 96
COVID-19 and the Endocrine System: A Comprehensive Review on the Theme
Lisco, G., Tullio, A. D., Stragapede, A., Solimando, A. G., Albanese, F., Capobianco, M., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., Vacca, A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132920 · Cited by 109
“Zoledronic acid at 5 mg once yearly may be considered as an alternative in patients who did not tolerate oral bisphosphonates or with gastrointestinal complaints or malabsorption [194].”
BackgroundDrugs for the management of osteoporosis: a review.
Khajuria, D. K., Razdan, R., & Mahapatra, D. R. (2011) · PubMed · Cited by 95
Gamsjaeger, S., Buchinger, B., Zwettler, E., Recker, R., Black, D., Gasser, J. A., Eriksen, E. F., Klaushofer, K., & Paschalis, E. P. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.180 · Cited by 94
“The phase III Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly—Pivotal Fracture Trial (HORIZON-PFT) enrolled 7736 postmenopausal women with osteoporosis and showed pronounced antifracture efficacy of yearly 5-mg infusions of ZOL with significant reductions of morphometric vertebral, clinical vert…”
BackgroundSelf-citationBisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle
Bertoldo, F., Santini, D., & Cascio, V. L. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1000 · Cited by 93
“In a randomized clinical trial of more than 7,000 postmenopausal women, 5 mg/year zoledronate for 3 years caused 1 case of ONJ, and 2 cases of ONJ were observed in the placebo group”
BackgroundLong-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties
Ma, S., Goh, E. L., Jin, A., Bhattacharya, R., Boughton, O. R., Patel, B., Karunaratne, A., Vo, N. T., Atwood, R., Cobb, J. P., et al. (2017) · Scientific Reports · doi:10.1038/srep43399 · Cited by 114
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
Horne, A. M., Mihov, B., & Reid, I. R. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0404-6 · Cited by 95
“Whether this matters in terms of fracture prevention is unknown, but it should be noted that zoledronate and denosumab have comparable anti-fracture efficacy despite differences in their effects on bone turnover and BMD [22, 23].”
BackgroundSelf-citationHodis, H. N., Collins, P., Mack, W. J., & Schierbeck, L. L. (2012) · Climacteric · doi:10.3109/13697137.2012.656401 · Cited by 107
Screening, diagnosis and treatment of osteoporosis: a brief review
Bernabei, R., Martone, A. M., Ortolani, E., Landi, F., & Marzetti, E. (2014) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2014.11.3.201 · Cited by 127
“One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis.”
BackgroundInfluentialEffects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women
Reid, I. R., Horne, A. M., Mihov, B., Stewart, A., Garratt, E., Bastin, S., & Gamble, G. D. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3860 · Cited by 93
“In contrast, the other phase 3 osteoporosis study of zoledronate reported by Black and colleagues((1)) found a relative risk of death of 1.”
BackgroundResultSelf-citationLangdahl, B. L. (2020) · Bone · doi:10.1016/j.bone.2020.115516 · Cited by 100
Cameron, I. D., Chen, J. S., MARCH, L. M., Simpson, J. M., Cumming, R. G., Seibel, M. J., & Sambrook, P. N. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091029 · Cited by 93
“Zoledronic acid is associated with a higher risk of concomitant acute-phase reactions than other bisphosphonates, which theoretically may enhance an elderly person’s underlying immune system status.((23)) However, it seems difficult to reconcile why zoledronic acid would reduce cardiovascular and infection-related mor…”
ResultManagement of osteoporosis of the oldest old
Rizzoli, R., Branco, J., Brandi, M. L., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C. C., Díez‐Pérez, A., Duder, J., Fielding, R. A., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2755-9 · Cited by 104
“References: 1 [85]; 2 [86]; 3 [87]; 4 [88]; 5 [89]; 6 [90]; 7 [91]; 8 [92]; 9 [93]; 10 [94]; 11 [95]; 12 [96]; 13 [97].”
BackgroundSelf-citationGreenspan, S. L., Brufsky, A., Lembersky, B. C., Bhattacharya, R. K., Vujevich, K. T., Perera, S., Sereika, S. M., & Vogel, V. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2967 · Cited by 94
Atypical Femoral Fractures: What Do We Know About Them?
Unnanuntana, A., Saleh, A., Mensah, K. A., Kleimeyer, J. P., & Lane, J. M. (2013) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.00568 · Cited by 98
Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy
Maier, J. D., & Levine, S. N. (2013) · Journal of Intensive Care Medicine · doi:10.1177/0885066613507530 · Cited by 107
Kalisch, L. M., Caughey, G. E., Roughead, E. E., & Gilbert, A. L. (2011) · Australian Prescriber · doi:10.18773/austprescr.2011.084 · Cited by 123
The rise and fall of the alveolar process: Dependency of teeth and metabolic aspects
Jonasson, G., Skoglund, I., & Rythén, M. (2018) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2018.09.016 · Cited by 99
Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis
Duong, L. T., LEUNG, A. T., & Langdahl, B. L. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-0051-0 · Cited by 92
Individualizing osteoporosis therapy
Silverman, S. L., & Christiansen, C. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1775-y · Cited by 96
“Bisphosphonates have also been shown to reduce the risk of nonvertebral fractures (risk reductions relative to placebo are 23% for daily alendronate, 20% for daily risedronate, and 25% for IV zoledronic acid) [12, 13, 15] and hip fractures (risk reductions relative to placebo are 53% for daily alendronate, 26% for dai…”
BackgroundPrevention and rehabilitation of osteoporosis
Kerschan‐Schindl, K. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-015-0417-y · Cited by 103
Brazilian guidelines for the diagnosis and treatment of postmenopausal osteoporosis
Radominski, S., Bernardo, W. M., de Paula, A. P., Albergaria, B., Moreira, C., Fernandes, C. E., Castro, C. H. D. M., Zerbini, C. A. F., Domiciano, D. S., de Mendonça, L. M. C., et al. (2017) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2017.07.001 · Cited by 150
Ye, C., Ebeling, P. R., & Kline, G. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01385-6 · Cited by 119
Drug-Induced Atrial Fibrillation
Kaakeh, Y., Overholser, B. R., Lopshire, J. C., & Tisdale, J. E. (2012) · Drugs · doi:10.2165/11633140-000000000-00000 · Cited by 90
Ebeling, P. R., Daly, R. M., Kerr, D. A., & Kimlin, M. G. (2013) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2013.tb04225.x · Cited by 94
Does Zoledronate Prevent Femoral Head Collapse from Osteonecrosis?
Lee, Y., Ha, Y., Cho, Y. J., Suh, K. T., Kim, S., Won, Y., Min, B.-W., Yoon, T. R., Kim, H. J., & Koo, K. (2015) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.n.01157 · Cited by 92
Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy
Leder, B. Z. (2018) · JBMR Plus · doi:10.1002/jbm4.10041 · Cited by 89
“One-year change in total hip BMD in osteoporotic women treated with (A) PTH (1-84), alendronate (ALN) and both drugs (COMBO), (B)”
BackgroundMethodSenn, C., Günther, B., Popp, A. W., Perrelet, R., Hans, D. B., & Lippuner, K. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2703-8 · Cited by 91
“evidence with regard to fracture risk reduction [2, 34-38].”
London, N. J. S., Garg, S. J., Moorthy, R. S., & Cunningham, E. T. (2013) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/1869-5760-3-43 · Cited by 97
“a systemic acute phase reaction, including the development of transient influenza-like symptoms, in approximately 30% of patients following the first intravenous infusion [49].”
Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review
Nguyen, H. H., van de Laarschot, D. M., Verkerk, A. J. M. H., Milat, F., Zillikens, M. C., & Ebeling, P. R. (2017) · JBMR Plus · doi:10.1002/jbm4.10024 · Cited by 96
“They are effective at reducing the risk of vertebral fractures by up to 70%((8)) and also reduce nonvertebral and hip fractures.”
BackgroundBisphosphonate-Based Strategies for Bone Tissue Engineering and Orthopedic Implants
Cattalini, J. P., Boccaccini, A. R., Lucangioli, S., & Mouriño, V. (2012) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2011.0737 · Cited by 87
Miki, R. A., Oetgen, M. E., Kirk, J., Insogna, K. L., & Lindskog, D. M. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.g.01246 · Cited by 93
Osteonecrosis of the Jaw in Patients Receiving Intravenous or Oral Bisphosphonates
King, A. E., & Umland, E. M. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.5.667 · Cited by 88
RANKL blockade prevents and treats aggressive osteosarcomas
Chen, Y., Di Grappa, M. A., Molyneux, S. D., McKee, T. D., Waterhouse, P., Penninger, J. M., & Khokha, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0295 · Cited by 88
Glucocorticoids, Inflammation and Bone
Güler-Yüksel, M., Hoes, J. N., Bultink, I. E. M., & Lems, W. F. (2018) · Calcified Tissue International · doi:10.1007/s00223-017-0335-7 · Cited by 100
Bone density of ambulatory adult patients receiving long-term anticonvulsant drug therapy.
Ashjazadeh, N., Zamani, A., Pourjafar, M., & b, G. R. O. A. (2009) · PubMed · Cited by 88
Kwon, Y., Kim, D., Ohe, J., Yoo, J.-Y., & Walter, C. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.04.067 · Cited by 87
Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis
Ramchand, S. K., & Leder, B. Z. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad496 · Cited by 86
Bisphosphonates, Old Friends of Bones and New Trends in Clinics
Barbosa, J. S., Paz, F. A. A., & Braga, S. S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01292 · Cited by 91
Increasing Options for the Treatment of Osteoporosis
Khosla, S. (2009) · New England Journal of Medicine · doi:10.1056/nejme0905480 · Cited by 86
Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss
Ofotokun, I., Titanji, K., Vikulina, T., Roser‐Page, S., Yamaguchi, M., Zayzafoon, M., Williams, I. R., & Weitzmann, M. N. (2015) · Nature Communications · doi:10.1038/ncomms9282 · Cited by 89
Anti-resorptive therapies for osteoporosis
Reid, I. R. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.08.002 · Cited by 95
Self-citationBiophosphonate-Related Osteonecrosis of the Jaws
Ruggiero, S. L., & Woo, S. (2008) · Dental Clinics of North America · doi:10.1016/j.cden.2007.09.002 · Cited by 100
Paget’s disease of bone: a review of epidemiology, pathophysiology and management
Shaker, J. L. (2009) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x09351779 · Cited by 93
Hines, S. L., Mincey, B. A., Dentchev, T., Sloan, J. A., Perez, E. A., Johnson, D. B., Schaefer, P., Alberts, S. R., Liu, H., Kahanic, S. P., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0332-2 · Cited by 91
A review of the clinical implications of bisphosphonates in dentistry
Borromeo, G. L., Tsao, C., Darby, I. B., & Ebeling, P. R. (2010) · Australian Dental Journal · doi:10.1111/j.1834-7819.2010.01283.x · Cited by 91
Management of complications of androgen deprivation therapy in the older man
Mohile, S. G., Mustian, K. M., Bylow, K. A., Hall, W. J., & Dale, W. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.09.004 · Cited by 91
“It is important to note that studies thus far have ot demonstrated prevention or improvement in risk or rate f fractures, although it has been shown that increasing BMD ith bisphosphonate therapy reduces osteoporotic fractures n postmenopausal women [127].”
BackgroundExtraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
Body, J. J., Bergmann, P., Boonen, S., Devogelaer, J.-P., Gielen, E., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J.-Y. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1891-8 · Cited by 96
“Some cases of prolonged musculoskeletal pain have been reported [130] in up to 20% to 25% of patients on alendronate and risedronate, as well as zoledronic acid [128, 131].”
BackgroundSelf-citationManagement of osteoporosis in rheumatoid arthritis patients
Hoes, J. N., Bultink, I. E. M., & Lems, W. F. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.997709 · Cited by 94
“Bisphosphonates (alendronate, risedronate, zoledronate) No data; GIOP: increased BMD (Zoledronate) Protect against joint erosions Fractures: significantly reduced risk Fractures (postmenopausal): 1 [54,55,85], BMD (GIOP): 1 [86], Erosions: 1 [72], RANKL inhibitor; denosumab BMD: increase Protect against joint erosions…”
BackgroundEffectiveness of a minimal resource fracture liaison service
Axelsson, K. F., Jacobsson, R. J., Lund, D., & Lorentzon, M. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3643-2 · Cited by 84
“70 % for vertebral fractures and 41 % for hip fractures [7].”
BackgroundJohnson, C. C., Gausden, E. B., Weiland, A. J., Lane, J. M., & Schreiber, J. J. (2016) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2016.04.016 · Cited by 87
Hiligsmann, M., Salas, M., Hughes, D. A., Manias, E., Gwadry-Sridhar, F. H., Linck, P., & Cowell, W. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2364-z · Cited by 84
The future of osteoporosis treatment – a research update
Lippuner, K. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13624 · Cited by 93
Zhou, J., Ma, X., Wang, T., & Zhai, S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3654-z · Cited by 88
Cosman, F., Crittenden, D. B., Ferrari, S., Lewiecki, E. M., Jaller-Raad, J. J., Zerbini, C. A. F., Milmont, C. E., Meisner, P. D., Libanati, C. R., & Grauer, A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3439 · Cited by 87
“7% over 3 years in the zoledronic acid HORIZON study,((18)) and 8.”
BackgroundSelf-citationA Review of Osteoporosis in the Older Adult
Alejandro, P., & Constantinescu, F. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.03.004 · Cited by 87
Moorthy, R. S., Moorthy, M. S., & Cunningham, E. T. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000530 · Cited by 86
Ringe, J. D., & Möller, G. (2009) · Rheumatology International · doi:10.1007/s00296-009-0940-5 · Cited by 88
“Bisphosphonates are today’s worldwide leading medication [7-16] and are recommended as first-line treatments for osteoporosis [1,2,17,18].”
BackgroundWatts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pessah‐Pollack, R., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.6.1016 · Cited by 83
Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study
Kang, J., Keller, J. J., & Lin, H. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2213-5 · Cited by 88
Bubbear, J. S., Gall, A., Middleton, F., Ferguson-Pell, M., Swaminathan, R., & Keen, R. W. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1221-6 · Cited by 82
“A single dose has been shown to suppress bone resorption for up to 12 months in a phase 2 trial in postmenopausal women [12], to significantly reduce rates of osteoporotic fracture in women with postmenopausal osteoporosis [13] and normalised alkaline phosphatase in patients treated for Paget’s disease for up to 24 mo…”
BackgroundMoe, S. M., Chen, N. X., Newman, C. L., Gattone, V. H., Organ, J. M., Chen, X., & Allen, M. R. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2089 · Cited by 85
“In humans, zoledronic acid has been shown to improve bone mineral density and reduce bone fractures in both primary and secondary prevention trials in patients with post-menopausal osteoporosis(20-22).”
BackgroundGregorio, S. D., del Río, L., Tolrà, J. R., Bonel, E., García, M., & Winzenrieth, R. (2015) · Bone · doi:10.1016/j.bone.2014.12.062 · Cited by 87
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications
Hiligsmann, M., Rabenda, V., Gathon, H.-J., Ethgen, O., & Reginster, J. (2010) · Calcified Tissue International · doi:10.1007/s00223-009-9329-4 · Cited by 81
“These values are very similar to those observed for once-yearly infusion of zoledronic acid, estimated at 41 and 77%, respectively [ 49 ].”
ResultKhajuria, D. K., Razdan, R., & Mahapatra, D. R. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.10.015 · Cited by 81
Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk
Fixen, C. W., & Tunoa, J. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00652-w · Cited by 80
Osteoporosis: An Update on Screening, Diagnosis, Evaluation, and Treatment
Sabri, S. A., Chavarria, J. C., Ackert‐Bicknell, C. L., Swanson, C. M., & Burger, E. L. (2022) · Orthopedics · doi:10.3928/01477447-20220719-03 · Cited by 103
Bock, O., & Felsenberg, D. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2134 · Cited by 93
“…class of drugs that unequivocally demonstrated their ability to reduce vertebral fracture risk in good-quality clinical trials (alendronate: Black et al 1996; Cummings et al 1998; rise-dronate: Harris et al 1999; Reginster et al 2000; ibandronate: Chesnut et al 2004; zoledronate: Black et al 2007).”
InfluentialDiretrizes para prevenção e tratamento da osteoporose induzida por glicocorticoide
Pereira, R. M. R., Carvalho, J. F. D., Paula, A. P., Zerbini, C., Domiciano, D. S., Gonçalves, H., Danowski, J. S., Marques Neto, J. F., Mendonça, L. M. C., Bezerra, M. C., et al. (2012) · Revista Brasileira de Reumatologia · doi:10.1590/s0482-50042012000400009 · Cited by 80
Activation of γδ T Cells by Bisphosphonates
Thompson, K., Roelofs, A. J., Jauhiainen, M., Mönkkönen, H., Mönkkönen, J., & Rogers, M. J. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1050-9_2 · Cited by 80
Management of osteoporosis in the elderly
Rizzoli, R., Bruyere, O., Cannata-Andia, J. B., Devogelaer, J.-P., Lyritis, G., Ringe, J. D., Vellas, B., & Reginster, J.-Y. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903169262 · Cited by 78
Frost, M. L., Siddique, M. M., Blake, G. M., Moore, A. E. B., Schleyer, P. J., Dunn, J., Somer, E. J., Marsden, P. K., Eastell, R., & Fogelman, I. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.305 · Cited by 82
Self-citationXu, X., Gou, W.-L., Wang, Y., Wang, Y., Guo, Q., Lu, Q., Lu, S., & Peng, J. C. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-303 · Cited by 79
“An increased incidence of atrial fibrillation was found in the 3-year Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON)-Pivotal Fracture Trial of yearly intravenous administration of zoledronate in postmenopausal women with osteoporosis [70].”
BackgroundTreatment needs and current options for postmenopausal osteoporosis
Gennari, L., Rotatori, S., Bianciardi, S., Nuti, R., & Merlotti, D. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1176147 · Cited by 85
Romosozumab for the treatment of osteoporosis
McClung, M. R. (2018) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2018.03.002 · Cited by 78
“That strategy effectively reduces the risk of important fractures and produces faster and greater increases in BMD and bone strength than with any current osteoporosis treatment [15,16,24,25] (Fig.”
BackgroundFerrari, S., Adachi, J. D., Lippuner, K., Zapalowski, C., Miller, P. D., Reginster, J.-Y., Törring, O., Kendler, D. L., Daizadeh, N. S., Wang, A., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3179-x · Cited by 78
Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence
Rabenda, V., Hiligsmann, M., & Reginster, J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903140533 · Cited by 84
Kajizono, M., Sada, H., Sugiura, Y., Soga, Y., Kitamura, Y., Matsuoka, J., & Sendo, T. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00385 · Cited by 95
Drug-Related Adverse Events of Osteoporosis Therapy
Khan, M., Cheung, A. M., & Khan, A. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.09.009 · Cited by 82
Mak, A., Cheung, M. W., Ho, R. C.-M., Cheak, A. A.-C., & Lau, C. S. (2009) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-10-113 · Cited by 77
“We therefore decided that rather than combining all the results of the RCTs, it would be more appropriate to perform a sensitivity analysis to test the robustness of the result of the 4 RCTs (the HORIZON Pivotal Fracture Trial, the HORIZON Recurrent Fracture Trial and the other is a report of the 2 FIT) by comparing w…”
BackgroundResultInfluentialTreatment of post-menopausal osteoporosis: beyond bisphosphonates
Ishtiaq, S., Fogelman, I., & Hampson, G. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0152-z · Cited by 86
“Firstly, bisphosphonates reduce non-vertebral and hip fractures by only 20–40 % whilst reducing vertebral fractures by approximately 60–70 % [51, 52].”
BackgroundWark, J. D., Bensen, W., Recknor, C. P., Ryabitseva, O. F., Chiodo, J., Mesenbrink, P. G., & de Villiers, T. J. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1563-8 · Cited by 76
Self-citationAllen, M. R., Kubek, D. J., & Burr, D. B. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090713 · Cited by 89
“While no head-to-head comparison exists, these systemic levels of remodeling suppression with cancer doses of zoledronic acid are similar in magnitude to those achieved with BP doses used for osteoporosis, either yearly intravenous zoledronic acid((23)) or more frequent doses of oral alendronate or risedronate.”
ResultSanderson, J., Martyn-St James, M., Stevens, J., Goka, E., Wong, R., Campbell, F., Selby, P., Gittoes, N., & Davis, S. (2016) · Bone · doi:10.1016/j.bone.2016.05.013 · Cited by 77
“[27] Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al.”
BackgroundMitchell, P., Åkesson, K., Chandran, M., Cooper, C. C., Ganda, K., & Schneider, M. C. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.09.008 · Cited by 85
Role of Hormone Therapy in the Management of Menopause
Shifren, J. L., & Schiff, I. (2010) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181d41191 · Cited by 76
Narongroeknawin, P., Danila, M. I., Humphreys, L. G., Barasch, A., & Curtis, J. R. (2010) · Special Care in Dentistry · doi:10.1111/j.1754-4505.2009.00128.x · Cited by 84
Bisphosphonate‐associated osteonecrosis of the jaw: does it occur in children?
Brown, J. J., Ramalingam, L., & Zacharin, M. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03189.x · Cited by 77
Nakamura, T., Fukunaga, M., Nakano, T., Kishimoto, H., Ito, M., Hagino, H., Sone, T., Taguchi, A., Tanaka, S., Ohashi, M., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3736-y · Cited by 80
“After 3 years of treatment, a significant risk reduction of vertebral fractures was observed [5].”
BackgroundDavis, S., James, M. M., Sanderson, J., Stevens, J., Goka, E., Rawdin, A., Sadler, S., Wong, R., Campbell, F., Stevenson, M., et al. (2016) · Health Technology Assessment · doi:10.3310/hta20780 · Cited by 83
“Zoledronic acid Zoledronic acid was evaluated against placebo in four RCTs.(56,59,77,79) ASSESSMENT OF CLINICAL EFFECTIVENESS”
BackgroundMethodInfluential
Metadata
- Authors
- Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T. F., Sellmeyer, D., Eriksen, E. F., & Cummings, S. R.
- Affiliations
- University of California, San Francisco (US)
- Lyon 1 Université (FR)
- University of Sheffield (GB)
- University of Auckland (NZ)
- KU Leuven (BE)
- University of Pittsburgh (US)
- Helen Hayes Hospital (US)
- Semmelweis University (HU)
- Chinese University of Hong Kong (HK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-05-03
- Volume
- 356
- Issue
- 18
- Pages
- 1809-1822
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1993035292
- Cited by
- 2,986
- References
- 34
- Citations by year
- 2026: 90 · 2025: 120 · 2024: 107 · 2023: 96 · 2022: 114 · 2021: 140 · 2020: 127 · 2019: 124 · 2018: 127 · 2017: 121 · 2016: 150 · 2015: 154 · 2014: 154 · 2013: 194 · 2012: 174
- FWCI
- 258.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- zoledronic acid, postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, vertebral fractures, hip fracture, bone mineral density, bone turnover markers, atrial fibrillation, renal function
- MeSH terms
- Zoledronic Acid, Aged, Aged, 80 and over, Atrial Fibrillation, Diphosphonates, Double-Blind Method, Drug Administration Schedule, Female, Hip Fractures, Humans, Imidazoles, Infusions, Intravenous, Risk, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Incidence, Spinal Fractures, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.